813 results on '"TABAK, Fehmi"'
Search Results
2. LBP-044 Robust reduction of HBsAg and HDV RNA levels with low risk for ALT elevations in JNJ-73763989 treated patients with chronic hepatitis D (CHD) and baseline HBsAg levels below 10, 000 IU/ml: part 2 of the REEF-D study
3. Urinary tract infections in older adults: associated factors for extended-spectrum beta-lactamase production
4. Safety of SARS-CoV-2 vaccination in patients with Behcet’s syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine
5. Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial
6. Clinical outcomes of geriatric patients with COVID-19: review of one-year data
7. Resistance Genes and Mortality in Carbapenem-resistant Klebsiella pneumoniae Bacteremias: Effects of the COVID-19 Pandemic.
8. The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet’s syndrome
9. Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report.
10. Tocilizumab in COVID-19: The Cerrahpaşa-PREDICT score
11. Colistin resistance increases 28-day mortality in bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae
12. Cost-Effectiveness Analysis of Remdesivir Treatment in COVID-19 Patients Requiring Low-Flow Oxygen Therapy: Payer Perspective in Turkey
13. Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly
14. Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a web-based survey
15. Change in species distribution and antifungal susceptibility of candidemias in an intensive care unit of a university hospital (10-year experience)
16. Treatment of Hepatitis C Virus-Infected Patients with Renal Failure
17. Investigation of the Prevalence of HBsAg, Anti-HCV, and Anti-HIV in a Prison in Turkey: A Point Prevalence Study
18. An easy-to-use nomogram for predicting in-hospital mortality risk in COVID-19: a retrospective cohort study in a university hospital
19. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment
20. Current Management of Chronic HBV Infection
21. Performance of Noninvasive Fibrosis Indices in Chronic Hepatitis B During Pretreatment and Post-Treatment Periods
22. Morbidity and Mortality in Immunocompromised COVID-19 Patients: Which Factors Are Responsible?
23. After the HIV/AIDS Congress 2022 (24-27 November 2022, Antalya): Gains, Challenges and Recommendations for the Future Response to HIV Infection in Türkiye
24. Flow Cytometric Analysis of Lymphocyte Subsets of Covid-19 Patients from A Single Centre in Turkey
25. Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis
26. Reactivation of Hepatitis B Virus Following Treatment of Hepatitis C Virus Infection in Coinfected Patients
27. Modeling the future of HIV in Turkey: Cost-effectiveness analysis of improving testing and diagnosis
28. Treatment with siRNA JNJ-73763989 plus nucleos (t)ide analogue (NA) decreases HBsAg and HDV RNA levels in patients with chronic hepatitis D (CHD): part 1 of the REEF-D study
29. Evaluation of Empirical and Preemptive Therapy Approaches of Invasive Mold Infections in Patients with Hematologic Malignancy.
30. Investigation of the Prevalence of HBsAg, Anti-HCV, and Anti-HIV in a Prison in Turkey: A Point Prevalence Study.
31. Discontinuation of Nucleos(t)ide Analog treatment in HBeAg-Negative Non-Cirrhotic Chronic Hepatitis B Patients: Real-Life Data of 20 Years.
32. The Changing Epidemiology of Delta Hepatitis in Türkiye over Three Decades: A Systematic Review
33. VERTEBRAL OSTEOMİYELİT: SON 10 YILDA NELER DEĞİŞTİ?
34. Diagnostic value of F-18 FDG PET/CT in patients with spondylodiscitis: Is dual time point imaging time worthy?
35. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome
36. Increase in transaminase levels during COVID-19 infection and its association with poor prognosis.
37. Factors Influencing HIV Infection in Children Born to HIV-Infected Mothers in Turkey.
38. Bağışıklığı Baskılanmış Hastalarda COVID-19 İnfeksiyonuna Bağlı Morbidite ve Mortalite: Hangi Faktörler Etkili?
39. HIV/AIDS Kongresi 2022'nin Ardından: Türkiye'de HIV İnfeksiyonu ile Mücadelede Kazanımlar, Zorluklar ve Öneriler.
40. Safety and Effectiveness of Tenofovir Alafenamide in the Turkish Population: A Systematic Review.
41. Epidemiology of HBV subgenotypes D
42. Eliminating Viral Hepatitis in Turkey: Achievements and Challenges
43. Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis
44. Real life efficacy, renal and lipid profile data of tenofovir alafenamide in switched chronic hepatitis B patients
45. Long-term follow-up of treatment-naïve HBeAg-negative patients with chronic hepatitis B
46. Incidence, Risk Factors, and Prognosis of Bloodstream Infections in COVID-19 Patients in Intensive Care: A Single-Center Observational Study
47. Changing Characteristics of Patients Living with HIV/AIDS After the COVID-19 Pandemic in Turkey
48. WED-418 A national multicenter study on initial antiviral treatment preferences on chronic hepatitis B: Entecavir versus Tenofovir disoproxil fumarate
49. Efficacy of tigecycline and vancomycin in experimental catheter-related Staphylococcus epidermidis infection: microbiological and electron microscopic analysis of biofilm
50. A pan-resistant Myroides odoratimimus catheter-related bacteremia in a COVID-19 patient and review of the literature
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.